诺桥制药

Nuobridge Pharmaceuticals is a clinical-stage biotechnology company based in Suzhou, China, focused on developing innovative small molecule drugs through targeted protein degradation (TPD) technologies. The company utilizes its proprietary platform to design molecular glues and PROTACs that target previously undruggable proteins involved in cancer and autoimmune disorders. Its lead candidate, NB-001, is a potent BTK degrader currently undergoing clinical evaluation for B-cell malignancies. Nuobridge's pipeline also includes several pre-clinical programs targeting various hematological and solid tumors. The company is supported by a team of industry veterans and leading venture capital firms in the Suzhou Industrial Park. Nuobridge aims to provide breakthrough therapies for patients worldwide by leveraging its deep expertise in medicinal chemistry and protein degradation.